Company / Net Debt per Share
Taysha Gene Therapies, Inc. Net Debt per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$1.32
FY2025
5-year range
-$2.97 / -$0.51
FY2021-FY2025
Trend
-158.7%
vs FY2024
Sector context
#61 of 82
Health Care
What the data says
At $-1.32, Taysha Gene Therapies, Inc.'s net debt per share ranks #22 of 82 in the Health Care sector. Net Debt per Share has fluctuated over the past 5 years, ranging from $-2.97 in FY2021 to $-0.51 in FY2024.
Based on SEC 10-K filings.
-1.32 in FY2025.
Increased from $-1.64 to $-1.32 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#22 of 82 in Health CareTop 26% of 82This company -$1.32 Sector average $13.70
▼
-109.6% below sector average
Key checks
Key Insights
- In FY2025, net debt per share decreased 158.7% year-over-year.
- Ranks #61 out of 82 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2024.
- Lowest net debt per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.32 | -158.7% |
| FY2024 | -$0.51 | +68.9% |
| FY2023 | -$1.64 | -26.1% |
| FY2022 | -$1.30 | +56.4% |
| FY2021 | -$2.97 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026